These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

101 related items for PubMed ID: 3313418

  • 1. Prostaglandin E1 in chronic arterial disease: a multicenter study.
    Trübestein G, Diehm C, Gruss JD, Horsch S.
    Prog Clin Biol Res; 1987; 242():445-51. PubMed ID: 3313418
    [No Abstract] [Full Text] [Related]

  • 2. Prostaglandin E1 in chronic arterial disease--a multicenter study.
    Trübestein G, Diehm C, Gruss JD, Horsch S.
    Vasa Suppl; 1987; 17():39-43. PubMed ID: 3470965
    [No Abstract] [Full Text] [Related]

  • 3. [Prostaglandin E1 in stage III and IV arterial occlusive diseases. results of a multicenter study].
    Trübestein G, Ludwig M, Diehm C, Gruss JD, Horsch S.
    Dtsch Med Wochenschr; 1987 Jun 12; 112(24):955-9. PubMed ID: 3297596
    [Abstract] [Full Text] [Related]

  • 4. [Prostaglandin E1 in decreased arterial perfusion].
    Pilger E, Bertuch H, Stark G, Hönigl K.
    Wien Klin Wochenschr; 1988 Jul 15; 100(14):490-5. PubMed ID: 3062908
    [Abstract] [Full Text] [Related]

  • 5. Intravenous prostaglandin E1 versus pentoxifylline therapy in chronic arterial occlusive disease--a controlled randomised multicenter study.
    Trübestein G, von Bary S, Breddin K, Diehm C, Gruss JD, Heinrich H, Horsch S, Kriessmann A, Maass U, Martin M.
    Vasa Suppl; 1989 Jul 15; 28():44-9. PubMed ID: 2692200
    [Abstract] [Full Text] [Related]

  • 6. Clinical application of prostaglandin E1 in cases of occlusive arterial disease.
    Mishima Y.
    Adv Prostaglandin Thromboxane Leukot Res; 1985 Jul 15; 15():547-8. PubMed ID: 2936166
    [Abstract] [Full Text] [Related]

  • 7. Clinical and haemostatic effects of intravenous prostaglandin E1 therapy in patients with peripheral arterial occlusive disease.
    Trifiletti A, Scamardi R, Pizzoleo MA, Sottilotta G, Soraci S, Attinà A, Bagnato L, Barbera N.
    Panminerva Med; 1999 Mar 15; 41(1):15-7. PubMed ID: 10230250
    [Abstract] [Full Text] [Related]

  • 8. Intraarterial prostaglandine E1 in arterial occlusive disease (AOD) stages III and IV.
    Herold A, Bruch HP, Hörl M, Düsel W.
    Prog Clin Biol Res; 1987 Mar 15; 242():439-44. PubMed ID: 2959966
    [Abstract] [Full Text] [Related]

  • 9. [The use of Vasaprostan (prostaglandin E1) in treating patients with obliterating arterial diseases of the lower extremities].
    Lebedev LV, Afonin DN.
    Vestn Khir Im I I Grek; 1993 Mar 15; 150(5-6):153-7. PubMed ID: 8091569
    [No Abstract] [Full Text] [Related]

  • 10. [Prostaglandin E1 between pathomechanism and therapy].
    Sinzinger H, Peskar BA.
    Wien Klin Wochenschr; 1988 Jul 15; 100(14):469-70. PubMed ID: 3062903
    [No Abstract] [Full Text] [Related]

  • 11. [Microcirculation in peripheral arterial occlusive diseases will improve. Prostaglandin can prevent surgery].
    MMW Fortschr Med; 2003 Dec 18; 145(51-52):41. PubMed ID: 14974333
    [No Abstract] [Full Text] [Related]

  • 12. Clinical effects of intravenously administered prostaglandin E1 in patients with rest pain due to peripheral obliterative arterial disease (POAD)--a preliminary report on a placebo-controlled double-blind study.
    Diehm C, Stammler F, Hübsch-Müller C, Eckstein HH, Simini B.
    Vasa Suppl; 1987 Dec 18; 17():52-6. PubMed ID: 3551154
    [No Abstract] [Full Text] [Related]

  • 13. [Prostaglandins including prostacyclin in the treatment of peripheral arterial occlusive disorders].
    Alexander K.
    Internist (Berl); 1989 Jul 18; 30(7):429-39. PubMed ID: 2670810
    [No Abstract] [Full Text] [Related]

  • 14. [Experience with intravenous prostaglandin E1 in stage II b arterial occlusive disease].
    Dé P, Hepp W.
    Vasa Suppl; 1990 Jul 18; 30():139-41. PubMed ID: 2075565
    [No Abstract] [Full Text] [Related]

  • 15. [Randomized study comparing the clinical effectiveness of intravenous prostaglandin E1 and intravenous pentoxifylline in patients with Fontaine stage IIb arterial occlusive disease].
    Hepp W, von Bary S, Corovic D, Diehm C, Mühe E, Rudofsky G, Scheffler P, Trübestein G, Vogelpohl M.
    Vasa Suppl; 1991 Jul 18; 33():348-9. PubMed ID: 1788753
    [No Abstract] [Full Text] [Related]

  • 16. [Effectiveness of intravenous infusion treatment of peripheral arterial occlusive disease with Trental--results of a multicenter double-blind study].
    Rudofsky G, Haussler KF, Künkel HP, Schneider-May H, Spengel F, Symann O, Werner HJ, Rössner M.
    Vasa Suppl; 1987 Jul 18; 20():375-8. PubMed ID: 3321494
    [No Abstract] [Full Text] [Related]

  • 17. Effect of prostaglandin E1 upon collateral vessels in peripheral occlusive arterial disease.
    Rudofsky G, Gerngross U.
    Prog Clin Biol Res; 1989 Jul 18; 301():407-9. PubMed ID: 2798455
    [No Abstract] [Full Text] [Related]

  • 18. Transcutaneous PO2 and laser Doppler flowmetry in patients with arterial occlusive disease receiving intraarterial infusions of PGE1 or nucleotide phosphates.
    Caspary L, Creutzig A, Alexander K.
    Prog Clin Biol Res; 1987 Jul 18; 242():433-8. PubMed ID: 2959965
    [No Abstract] [Full Text] [Related]

  • 19. [Cardiopulmonary effects of prostaglandin E1. Aspects of drug safety].
    Heidrich H, Breddin HK, Rudofsky G, Scheffler P.
    Med Klin (Munich); 1992 Mar 15; 87(3):123-30. PubMed ID: 1579089
    [No Abstract] [Full Text] [Related]

  • 20. Iontophoretic administration of prostaglandin E1 in peripheral arterial occlusive disease.
    Sakurai T, Yamamura K.
    Ann Pharmacother; 2003 May 15; 37(5):747. PubMed ID: 12708957
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.